ReviewCurrent rheumatology reports2025
Advances in Drug Research Targeting Neutrophils for the Treatment of Rheumatoid Arthritis.
Review in Current rheumatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association between neutrophil-to-lymphocyte ratio and the prognosis of patients with rheumatoid arthritis: a meta-analysis.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of the reviewRheumatoid arthritis (RA) is a complex chronic autoimmune disease characterized by abnormal activation of immune cells and persistent inflammatory responses. As an emerging immune mechanism, neutrophil extracellular traps (NETs) play a significant role in the pathogenesis and progression of RA. RECENT
findingsIn recent years, studies have revealed that various drugs and natural products can significantly influence the inflammatory microenvironment and tissue damage in RA by regulating the formation and release of NETs. This article systematically reviews currently marketed and investigational agents, including conventional antirheumatic drugs, biological agents, small-molecule inhibitors, Chinese herbal medicines, and nanoformulations, with a focus on evaluating their regulatory effects on NETs in RA and associated therapeutic outcomes. Through a comprehensive analysis of drug mechanisms, clinical efficacy, and safety profiles, this review explores the balance point of NETs-modulating therapeutic strategies, providing a theoretical basis and future research directions for precision medicine in RA.
Indexed as
Identifiers
40928697What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.